4,455.00
-55(-1.22%)
Currency In KRW
Address
Korea Bio Park Building B
Seongnam, 13488
Korea, Republic of
Phone
82 3 1628 3200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
86
First IPO Date
September 15, 2009
| Name | Title | Pay | Year Born |
| Chul Jun Hyun | Auditor & Director | 0 | N/A |
| Jong Sup Park | Chief Medical Officer | 0 | N/A |
| Jungwon Woo | President & Director | 0 | N/A |
| Neil K. Warma | President & Director | 0 | 1963 |
| Young-Chul Sung | Founder & Chairman of the Scientific Advisory Board | 0 | 1956 |
| Hyun Jin Park | EVP of Corporate Development | 0 | N/A |
| Jang Hee Lee | EVP of Operations | 0 | N/A |
| Jongsoo Lee | Senior Manager of IR & PR | 0 | N/A |
| Ki Yong Kim | SVP of Bio Research Institute | 0 | N/A |
| Sung-June Hong | Executive Vice President, Chief Financial Officer & Director | 0 | 1965 |
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.